Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten Boers

Showing results (11-20 of 395) with videos related to

Pageof 40
Sort By:
Annals of Internal Medicine|October 15, 2019
Older Drugs With Limited Trial Evidence: Are They Worth the Expense?Maarten Boers
Annals of the Rheumatic Diseases|April 20, 2023
Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?"Maarten Boers
Nederlands Tijdschrift Voor Geneeskunde|February 28, 2024
[Longterm treatment with glucocorticoids: problem or solution?]Maarten Boers
Arthritis and Rheumatism|February 1, 2011
Syk kinase inhibitors for rheumatoid arthritis: trials and tribulationsMaarten Boers
Annals of the Rheumatic Diseases|December 17, 2009
A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicalsMaarten Boers
Clinical and Experimental Rheumatology|November 18, 2017
More erroneous statements about the use of frequentist statistical methods in medical researchMaarten Boers
The Journal of Rheumatology|April 5, 2007
Studying the benefit/risk ratio of glucocorticoids in rheumatoid arthritisMaarten Boers
Arthritis and Rheumatism|December 30, 2006
Effect of dosage on coxib- or nonsteroidal antiinflammatory drug-associated cardiovascular risk? Comment on the article by Solomon et alMaarten Boers
Arthritis and Rheumatism|October 31, 2007
Why publish a secondary analysis of only one treatment group in the Behandelstrategieën voor Reumatoide Artritis trial? Comment on the article by van der Bijl et alMaarten Boers
Arthritis & Rheumatology (Hoboken, N.J.)|January 8, 2025
Avoiding placebo as control treatment in rheumatology trials: can we do better? Comment on the article by Kivitz et alMaarten Boers
Pageof 40

Showing results (11-20 of 395) with videos related to

Sort By:
Pageof 40
Annals of Internal Medicine|October 15, 2019
Older Drugs With Limited Trial Evidence: Are They Worth the Expense?Maarten Boers
Annals of the Rheumatic Diseases|April 20, 2023
Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?"Maarten Boers
Nederlands Tijdschrift Voor Geneeskunde|February 28, 2024
[Longterm treatment with glucocorticoids: problem or solution?]Maarten Boers
Arthritis and Rheumatism|February 1, 2011
Syk kinase inhibitors for rheumatoid arthritis: trials and tribulationsMaarten Boers
Annals of the Rheumatic Diseases|December 17, 2009
A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicalsMaarten Boers
Clinical and Experimental Rheumatology|November 18, 2017
More erroneous statements about the use of frequentist statistical methods in medical researchMaarten Boers
The Journal of Rheumatology|April 5, 2007
Studying the benefit/risk ratio of glucocorticoids in rheumatoid arthritisMaarten Boers
Arthritis and Rheumatism|December 30, 2006
Effect of dosage on coxib- or nonsteroidal antiinflammatory drug-associated cardiovascular risk? Comment on the article by Solomon et alMaarten Boers
Arthritis and Rheumatism|October 31, 2007
Why publish a secondary analysis of only one treatment group in the Behandelstrategieën voor Reumatoide Artritis trial? Comment on the article by van der Bijl et alMaarten Boers
Arthritis & Rheumatology (Hoboken, N.J.)|January 8, 2025
Avoiding placebo as control treatment in rheumatology trials: can we do better? Comment on the article by Kivitz et alMaarten Boers
Pageof 40